ArticleOncogene2026
An ex vivo permissivity assay to assess replication of the oncolytic virus VSV-GP in patient-derived tumor samples.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The sparking interest in oncolytic viruses (OV) faces challenges in clinical translation due to limitations of pre-clinical models and the lack of predictive biomarkers for OV activity. Furthermore, functional assays which could determine permissivity of human tumors to OVs in a straightforward way are still lacking. Here, we present a novel ex vivo permissivity assay to precisely quantify replication of OVs in viable patient-derived tumors. As example, replication of reporter protein-expressing oncolytic VSV-GP variants was tracked via fluorescence, luminescence or qPCR across 133 patient-derived tumor samples (resection fragments/slices, biopsies) spanning more than 20 tumor entities. Based on the results of our comprehensive testing and by employing VSV-GP-NanoLuc-Katushka, we were able to establish a semi-automated permissivity assay with minimal hands-on time, allowing robust and real-time tracking of viral replication in patient-derived tumor samples. Given the urgent demand for innovative cancer treatments, this novel permissivity assay could be applied to select patients with tumors permissive to OV replication and might thus also show an enhanced clinical response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.